Loading...
Disclaimer: Informational only — not medical advice. AI hypotheses are not clinically validated. Medic Oath is for informational and educational purposes only — not medical advice. AI-generated hypotheses have not been clinically validated. Always consult a qualified healthcare professional. Privacy · Terms
A rare autosomal recessive amino acid metabolism disorder characterized by variable degrees of hyperammonemia leading to progressive loss of developmental milestones and spasticity in the absence of treatment.
PEGylated arginine deiminase from Mycoplasma hominis converts arginine to citrulline and ammonia, bypassing defective ARG1. PEGylation extends half-life and reduces immunogenicity. Citrulline is non-toxic and can be converted to ornithine via ornithine transcarbamylase, maintaining urea cycle flux without arginine accumulation.
Metformin activates AMPK, which phosphorylates and downregulates CAT1 (SLC7A1) and CAT2 (SLC7A2) arginine transporters. Reduced cellular arginine uptake decreases intracellular arginine burden. AMPK also phosphorylates acetyl-CoA carboxylase, shifting metabolism toward fatty acid oxidation and away from arginine-dependent biosynthetic pathways.
Ornithine α-ketoglutarate provides ornithine substrate for ornithine transcarbamylase, maintaining urea cycle flux downstream of ARG1 block. Phenylbutyrate conjugates with glutamine via glutamine-N-acyltransferase, creating alternative nitrogen disposal pathway. Combined approach addresses both urea cycle restoration and nitrogen scavenging.
Engineered Lactobacillus plantarum expressing arginine decarboxylase converts dietary arginine to agmatine in gut lumen, reducing systemic arginine absorption. Agmatine is further metabolized by bacterial agmatinase to putrescine and urea. Targeted gut colonization reduces arginine bioavailability while maintaining beneficial microbiome effects.
Curcumin upregulates SIRT1 deacetylase activity, promoting PGC-1α deacetylation and mitochondrial biogenesis. Enhanced mitochondrial function improves alternative arginine metabolism through ornithine aminotransferase (OAT) and reduces toxic arginine accumulation. SIRT1 also deacetylates p53, reducing neuronal apoptosis triggered by hyperargininemia.
Bacosides A and B from Bacopa monnieri stabilize neuronal nitric oxide synthase (NOS1) dimers by enhancing BH4 cofactor availability through GTP cyclohydrolase I upregulation. This prevents NOS uncoupling and reduces superoxide generation from excess arginine substrate. Bacosides also upregulate SOD2 expression, enhancing antioxidant capacity.
Saikosaponin D activates TFEB translocation to nucleus, upregulating lysosomal biogenesis genes including LAMP1, CTSD, and ATP6V1H. Enhanced autophagy-lysosome system degrades accumulated arginine-protein aggregates and damaged mitochondria. TFEB also upregulates arginase-2 (ARG2) expression, providing partial functional compensation for ARG1 deficiency.